Jefferies analyst Eun Yang started RA Pharmaceuticals with a Buy rating and $25 price target. The analyst sees greater than 100% potential upside should the Phase II data for RA101495 in paroxysmal nocturnal hemoglobinuria patients be positive in the second half of 2017.